{"created":"2023-05-15T14:36:48.075212+00:00","id":47415,"links":{},"metadata":{"_buckets":{"deposit":"25ec8c71-d377-485b-82b2-9b5582c0737e"},"_deposit":{"created_by":1,"id":"47415","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"47415"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00047415","sets":["1"]},"author_link":["474779","474778","474771","474768","474777","474774","474773","474767","474772","474775","474770","474780","474769","474776"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"8","bibliographicPageEnd":"358","bibliographicPageStart":"349","bibliographicVolumeNumber":"30","bibliographic_titles":[{"bibliographic_title":"Cancer biotherapy & radiopharmaceuticals"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"(111)In-labeled trastuzumab modified with nuclear localizing signal (NLS) peptides ((111)In-trastuzumab-NLS) efficiently delivers an Auger electron (AE) emitter (111)In into the cell nucleus and is thus a promising radiopharmaceutical in AE radioimmunotherapy (AE-RIT) for targeted killing of HER2-positive cancer. However, further improvement of its therapeutic efficacy is required. In this study, the authors show a transcriptomic approach to identify potential targets for enhancing the cytotoxic effects of (111)In-trastuzumab-NLS. They generated two types of (111)In-trastuzumab-NLS harboring different numbers of NLS peptides, (111)In-trastuzumab-NLS-S and -L. These radioimmunoconjugates (230 and 460 kBq) showed a significant higher cytotoxicity to SKBR3 human breast cancer cells overexpressing HER2 compared to (111)In-trastuzumab. Microarray analysis revealed that NF-kB-related genes (38 genes) were significantly changed in transcription by (111)In trastuzumab-NLS-L (230 kBq) treatment. Quantitative reverse transcription polymerase chain reaction confirmed the microarray data by showing transcriptional alternation of selected NF-κB target genes in cells treated with (111)In-trastuzumab-NLS-L. Interestingly, bortezomib, a drug known as a NF-κB modulator, significantly enhanced the cytotoxicity of (111)In-trastuzumab-NLS-L in SKBR3 cells. Taken together, the transcriptome data suggest the possibility that the modulation of NF-kB signaling activity is a molecular signature of (111)In-trastuzumab-NLS and coadministration of bortezomib may be efficacious in enhancement of AE-RIT with (111)In-trastuzumab-NLS.","subitem_description_type":"Abstract"}]},"item_8_relation_13":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"26447839","subitem_relation_type_select":"PMID"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1084-9785","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Keiko, Li Huizi"}],"nameIdentifiers":[{"nameIdentifier":"474767","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Morokoshi, Yukie"}],"nameIdentifiers":[{"nameIdentifier":"474768","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Daino, Kazuhiro"}],"nameIdentifiers":[{"nameIdentifier":"474769","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Furukawa, Takako"}],"nameIdentifiers":[{"nameIdentifier":"474770","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"474771","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saga, Tsuneo"}],"nameIdentifiers":[{"nameIdentifier":"474772","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hasegawa, Sumitaka"}],"nameIdentifiers":[{"nameIdentifier":"474773","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"李 惠子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"474774","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"諸越 幸恵","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"474775","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"臺野 和広","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"474776","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"古川 高子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"474777","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"474778","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐賀 恒夫","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"474779","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川 純崇","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"474780","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies."}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-05-18"},"publish_date":"2016-05-18","publish_status":"0","recid":"47415","relation_version_is_last":true,"title":["Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies."],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:40:07.770452+00:00"}